Statements (53)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:vaccine
|
| gptkbp:approves |
gptkb:2005
|
| gptkbp:average_temperature |
2 to 8 degrees Celsius
|
| gptkbp:clinical_trial |
Phase 3
|
| gptkbp:clinical_use |
booster vaccination
|
| gptkbp:contraindication |
severe allergic reaction to vaccine components
moderate to severe illness |
| gptkbp:dosage_form |
suspension for injection
|
| gptkbp:effective_date |
FDA approved
|
| https://www.w3.org/2000/01/rdf-schema#label |
Boostrix
|
| gptkbp:ingredients |
gptkb:diphtheria_toxoid
gptkb:tetanus_toxoid pertussis antigens |
| gptkbp:is_recommended_for |
adults
adolescents |
| gptkbp:is_vulnerable_to |
refrigerated
global distribution WHO recommendations inactivated vaccine part of routine immunization programs developed in the 1990s CDC recommendations approved in multiple countries administered by healthcare professionals combination vaccine reduced incidence of diseases booster dose for adults high efficacy against diphtheria high efficacy against pertussis high efficacy against tetanus ongoing research for new formulations single dose for adolescents vaccine effectiveness monitoring |
| gptkbp:manufacturer |
gptkb:Glaxo_Smith_Kline
|
| gptkbp:market |
ongoing
|
| gptkbp:marketed_as |
gptkb:Boostrix_vaccine
|
| gptkbp:route_of_administration |
intramuscular injection
|
| gptkbp:safety_features |
generally well tolerated
rare serious adverse events |
| gptkbp:side_effect |
fatigue
headache nausea required fever pain at injection site |
| gptkbp:target_audience |
pregnant women
healthcare workers travelers to endemic areas |
| gptkbp:used_for |
prevention of diphtheria
prevention of pertussis prevention of tetanus |
| gptkbp:bfsParent |
gptkb:GSK
|
| gptkbp:bfsLayer |
4
|